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Abstract 
 
Abnormal fear conditioning processes (including fear acquisition and conditioned 
fear-generalization) have been implicated in the pathogenesis of anxiety disorders. Previous 
research has shown that individuals with panic disorder present enhanced conditioned 
fear-generalization in comparison to healthy controls. Enhanced conditioned 
fear-generalization could also characterize generalized anxiety disorder (GAD), but 
research so far is inconclusive. An important confounding factor in previous research is 
comorbidity. The present study examined conditioned fear-acquisition and 
fear-generalization in 28 patients with GAD and 30 healthy controls using a recently 
developed fear acquisition and generalization paradigm assessing fear-potentiated startle 
and online expectancies of the unconditioned stimulus. Analyses focused on GAD patients 
without comorbidity but included also patients with comorbid anxiety disorders. Patients 
and controls did not differ as regards fear acquisition. However, contrary to our hypothesis, 
both groups did not differ either in most indexes of conditioned fear-generalization. 
Moreover, dimensional measures of GAD symptoms were not correlated with conditioned 
fear-generalization indexes. Similar results were obtained for patients with comorbidity. 
These results suggest that conditioned fear-generalization is not enhanced in GAD. Results 
are discussed with special attention to the possible effects of comorbidity on fear learning 
abnormalities. 
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Introduction 
Fear conditioning is a form of associative learning by which a neutral stimulus is 
repeatedly paired with an aversive unconditioned stimulus (US), becoming a conditioned 
stimulus (CS), which is capable of eliciting a conditioned fear response (CR). Although 
fear conditioning is an adaptive form of learning, it may become a source of pathology 
when anxious reactivity to a CS persists in the absence of a CS/US association. 
Several fear conditioning processes have been implicated in the pathogenesis of 
anxiety disorders (Lissek et al., 2005; Mineka & Zinbarg, 2006). These processes include 
acquisition, within-session extinction, extinction recall, conditioned inhibition and 
conditioned fear-generalization. For example, an enhanced fear acquisition may be 
characteristic of social phobia (Lissek et al., 2008a), generalized anxiety disorder (GAD; 
Thayer, Friedman, Borkovec, Johnsen, & Molina, 2000), or post-traumatic stress disorder 
(PTSD; Orr et al., 2000; Peri, Ben-Shakhar, Orr, & Shalev, 2000). Impaired within-session 
fear extinction has been shown for individuals with panic disorder (PD; Michael, Blechert, 
Vriends, Margraf, & Wilhelm, 2007; Otto et al., 2014) or GAD (Pitman & Orr, 1986), 
whereas impaired extinction recall could be present in PTSD (Milad et al., 2008) or 
obsessive-compulsive disorder (OCD; Milad et al., 2013). Moreover, conditioned inhibition 
deficits may characterize PTSD (Jovanovic et al., 2009, 2010). However, these results have 
not been always replicated. For example, “normal” (i.e. not enhanced) fear acquisition has 
been reported in PD (Michael et al., 2007), social phobia  (Tinoco-González et al., 2013; 
Hermann, Ziegler, Birbaumer, & Flor 2002) or GAD (Pitman & Orr, 1986).  
Conditioned fear-generalization occurs when fear CRs extend to a range of novel 
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stimuli (generalization stimuli) that resemble the original CS. It can become maladaptive 
(i.e. excessive) when some of these stimuli are perceived as harmful given the similarity 
and (non)discriminability to previously learned stimuli (Dunsmoor, Mitroff, & La Bar, 
2009).  
The possible role of conditioned fear-generalization in pathological anxiety has 
gained increased research recognition during the last decade (Vervliet, Vansteenwegen, & 
Eelen, 2004; Vervliet, Vansteenwegen, Baeyens, Hermans, & Eelen, 2005; Lissek et al., 
2008b, 2010, 2013; Hajcak et al., 2009). Indeed, recent etiological accounts of anxiety 
disorders suggest that conditioned fear-generalization could be a central pathogenic marker 
of some anxiety disorders (Lissek, 2012), although prospective studies supporting this 
assumption are lacking. In several case-control studies, individuals with specific anxiety 
disorders have shown abnormal (i.e. enhanced) conditioned fear- generalization in 
comparison to healthy controls. This has been the case for PD (Lissek et al., 2010), PTSD 
(cited in Lissek et al., 2008b), and recently, GAD (Lissek et al., 2013). In GAD, 
generalization may contribute to an increase in the number of events triggering worry, the 
hallmark of the disorder (Greenberg, Carlson, Cha, Hajcak, & Mujica-Parodi, 2013). It may 
also contribute to worry about topics that only have a moderate relatedness with the 
original triggers (Lissek et al., 2013). 
In the aforementioned study, Lissek et al. (2013) compared fear acquisition and 
conditioned fear-generalization using a validated experimental paradigm (Lissek et al., 
2008b) among 22 patients with GAD and 26 healthy controls. GAD patients showed 
abnormally broad conditioned fear-generalization gradients, compared to controls, as 
measured by the fear-potentiated startle, despite showing similar fear acquisition. However, 
in a recent study no evidence for enhanced conditioned fear-generalization in subjective 
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(risk ratings) or autonomic (pupillary response) measures was found in women with GAD 
in comparison to healthy controls (Greenberg et al., 2013). A limitation of these two studies 
on conditioned fear-generalization in GAD is that almost 50% of patients had a comorbid 
anxiety (Lissek et al., 2013) or depressive (Greenberg et al., 2013) disorder. This casts 
doubts about the specificity of conditioned fear-generalization impairments in GAD. 
Additionally, studies on the role of certain individual differences variables that are closely 
related to GAD (e.g., trait-anxiety or trait-worry) in non-clinical or sub-clinical individuals 
using fear conditioning paradigms have also provided inconsistent results. For example, 
high-trait anxiety has been associated with enhanced fear acquisition in some studies 
(Indovina, Robbins, Núñez-Elizalde, Dunn, & Bishop, 2011), but not in others 
(Torrents-Rodas et al., 2013). The same is true for trait-worry (Joos, Vansteenwegen, & 
Hermans, 2012; Otto et al., 2007). These studies used relatively different conditioning tasks 
and a possible explanation for the inconsistent results is that ambiguous tasks may obscure 
the effects of trait anxiety (Torrents-Rodas et al, 2012; see Beckers, Krypotos, Boddez, 
Effting, & Kindt, 2013).  
Although fear conditioning processes do not feature prominently among current 
theoretical explanations of GAD (see Behar, DiMarco, Hekler, Mohlman, & Staples 2009; 
Newman, Llera, Erickson, Przeworski, & Castonguay, 2013), some typical GAD 
characteristics such as the tendency to interpret ambiguous stimuli as threatening (see 
Lissek et al., 2013) suggest that these processes may have an important role in the disorder 
and that more studies in the field are needed. In the present study, we examined conditioned 
fear-acquisition and fear-generalization in GAD patients using a fear conditioning paradigm 
assessing fear-potentiated startle (FPS) and subjective responses. To address the issue of 
comorbidity, we focused our analyses on GAD participants without comorbidity but 
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conducted additional separate analyses in GAD patients with comorbid anxiety disorders. 
Based on previous research, we predicted that GAD patients would show enhanced 
conditioned fear-generalization in comparison to healthy controls (Lissek et al., 2013) but 
we expected that GAD patients and healthy controls would show similar fear acquisition 
(Lissek et al., 2013).  
 
Method 
Participants and procedure 
Participants were recruited among university students by advertisements to 
participate in a study on “physical responses to emotions”. We did not rely on clinical 
referral to facilitate the recruitment of unmedicated GAD participants. Initially, 2005 
individuals were screened with the Spanish version of the Carroll-Davidson screening 
scale for DSM-IV Generalized Anxiety Disorder (CD-GAD scale; Bobes, García-Calvo, 
Prieto, García-García, & Rico-Villademor, 2006) via a secure web system. Those scoring 
high (> 6; percentile 74) or low (< 3; percentile 37) on the CD-GAD scale were offered to 
participate in the study and, if accepted, were interviewed by a licensed clinical 
psychologist not involved in the experimental phase using the Mini International 
Neuropsychiatric Interview (MINI, Sheehan et al., 1998).  
Exclusion criteria for all participants were 1) pharmacological medication or 
medical pathology (e.g. neurological disorders) capable of interfering with study objectives, 
2) use of illicit drugs, 3) pregnancy, 4) psychomotor delay (item A3c of the MINI), and 5) 
not being Spanish-speaking. Additional exclusion criteria for GAD participants (also 
assessed with the MINI) were presence of current major depressive disorder or suicidal 
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ideation and past history of major depressive disorder, bipolar disorder, or psychotic 
disorder. 
The final sample consisted of 28 individuals (n=5 with comorbid social anxiety 
disorder) who fulfilled current diagnostic criteria of GAD and 30 healthy controls (HC) 
who did not fulfill criteria for any present or past mental disorder. Healthy controls were 
distilled from the initial screening sample based on their GAD scale scores (GAD <3) and 
optimal matching with regard to age and gender. Demographic and clinical characteristics 
of the participants are presented in Table 1. 
 
Measures 
 Our screening instrument, the CD-GAD scale is a 12-item scale that assesses GAD 
symptoms during the past 6 months based on DSM-IV-TR criteria. A score of 6 or above 
indicates a positive screen for GAD. The Spanish version of the CD-GAD (Bobes et al., 
2006) has shown similar psychometric properties to the original version.  
The MINI is a widely used structured psychiatric interview that assesses current and 
life-time mental disorders and has shown to have good concordance with other diagnostic 
measures, and good interrater and test-retest reliability (Sheehan et al., 1998; Lecubrier et 
al., 1997). The Spanish validated version of the MINI was used (Bobes, 1998).  
During the experimental session, all participants completed the validated Spanish 
versions of the State-Trait Anxiety Inventory (STAI-S and STAI-T; Spielberger, Gorsuch & 
Lushene, 1982), which measure state (i.e. current) and trait (i.e. dispositional) anxiety, and 
have sound psychometric properties (Spielberger, Gorsuch & Lushene, 1982). The STAI-T 
has been used as an outcome measure in several treatment trials in GAD (Fisher & 
Durham, 1999).  
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Participants also completed the Spanish version (Sandín, Valiente, Chorot & Santed, 
2007) of the Anxiety Sensitivity Index-3, a measure of fear of anxiety symptoms with 
excellent psychometric properties (Sandín et al., 2007). 
All participants were paid 15€ and were asked to sign an informed consent, which 
was previously approved by the corresponding institution’s Ethical Research Committee, 
after describing the experimental procedure in detail. 
 
Table 1.  
 
Demographic and clinical characteristics of participants and variables related to the 
experimental procedure. 
 
Group 
 Non-comorbid GAD 
Participants1  
(n=23) 
Healthy Controls (n=30)  
Variable Mean SD Mean SD Significancea 
Age 24.30 5.37 26.60 4.34 p = .10 
CD-GAD (0-12) 9.27 2.03 0.63 1.25 p< .001 
ASI-3 (0-64) 26.09 11.88 11.53 4.48 p< .001 
STAI-Sb (0-60) 17.02 8.69 9.27 5.01 p< .001 
STAI-Tb (0-60) 36.65 9.49 10.30 6.50 p< .001 
Shock intensity (mA) 3.71 1.00 3.96 1.07 p = .39 
Shock discomfort (1-10) 5.17 2.27 4.67 2.01 p = .39 
Startle probe discomfort (1-10) 7.78 1.45 6.70 1.88 p = .03 
 N % N %  
Female Gender 17 73.9 17 56.7 p = .19 
Contingency-unaware 6 26.1 5 16.7 p = .40 
CD-GAD, Carroll-Davidson screening scale for DSM-IV Generalized Anxiety Disorder; ASI, Anxiety 
Sensitivity Index-3; STAI-S State-Trait Anxiety Inventory, State Version; STAI-T, State-Trait Anxiety 
Inventory, Trait Version; SD, Standard Deviation 
aIndependent sample t tests (except for gender and awareness which were assessed with a Chi square) 
bScores range from 0 to 60 in the Spanish version of the STAI-S and STAI-T. 
                                                           
1The corresponding numbers for the GAD subjects with comorbidity (n=28) were Mean (SD): Age = 25.11 (6.39); CD-GAD = 9.36 
(2.11); ASI-3 = 26.04 (11.77); STAI-S = 18.68 (9.11); STAI-T = 36.82 (8.89); Shock intensity = 3.75 (0.99); Shock discomfort = 5.21 
(2.33); Startle probe discomfort = 7.71 (1.56); Female gender = 71.4%; Contingency-unaware = 25%. 
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Stimuli and procedure 
We used the paradigm developed by Lissek and colleagues, which consists of three 
experimental phases (pre-acquisition, acquisition, and generalization) preceded by one 
habituation phase (Lissek et al., 2008b) and which allows the study of both conditioned fear 
acquisition and generalization.  
Ten rings of gradually increasing size were presented for 8 s on a computer monitor 
and served as conditioned stimuli (CSs) and generalization stimuli (GSs). The diameter of 
the smallest ring was 5.08 cm and subsequent rings increased by 15%2. The rings at the two 
extremes of this size continuum served as CSs. For half of the participants in each group, 
the smallest ring was the CS+ (paired with the US before its offset) and the largest was the 
CS-; for the remaining participants the pairing was reversed. The intermediate rings were 
used to test conditioned generalization. A fixation-cross (size: 8.23 cm) appeared on the 
screen when no stimulus was presented (inter-trial interval, ITI). The US was an electric 
shock of 10 ms duration, with an intensity adjusted for each participant as being “highly 
uncomfortable but not painful”, delivered to the volar surface of the right forearm. The 
acoustic startle probe was a 50 ms duration, 102 dB(A) burst of white noise with a near 
instantaneous rise time, presented binaurally through headphones. Startle probes were 
presented 4 or 5 s after the beginning of odd trials, inter-probe intervals (IPIs) ranged from 
18 to 25 s. ITI durations (9 to 17 s) were adjusted to keep IPIs within the specified range. 
During even trials, online ratings of perceived risk of shock for each stimulus were 
obtained (1 = no risk, 2 = moderate risk, 3 = high risk). One or 2 s after trial onset, a 
                                                           
2As in Lissek et al., 2008b, the diameter for the smallest ring (Ring #1) was 2.00 in and subsequent rings increased by 15% with Ring #2 
increasing 15% from Ring #1 (2.30 in), Ring #3 increasing 30% from Ring #1 (2.60 in), Ring #4 increasing 45% from #1 (2.90 in), and 
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question (Level of risk?) cued participants to respond as quickly as possible using a 
computer keyboard. Stimulus timing and response recording were controlled by the 
commercial system Presentation (Neurobehavioral Systems Inc, Version 0.70, 
www.neurobs.com). 
Participants were not instructed about the CS-US contingency, but were told that 
they might learn to predict the shock if they attended to the presented stimuli. Then the 
electrodes were placed, and the intensity of the shock was adjusted. After placing the 
headphones, nine startle probes were presented to reduce initial startle reactivity 
(habituation). Pre-acquisition consisted of six CS+ and six CS- trials presented in the 
absence of the US. Acquisition consisted of 12 CS+ (with a 75% reinforcement) and 12 
CS- trials. Generalization consisted of 12 CS+ (with a 50% reinforcement), 12 CS-, and six 
trials from each of the eight GSs sizes. Trials for all the phases were presented in 
quasi-random order with the restriction that no more than two stimuli of the same class 
appeared consecutively. Furthermore, to ensure an even distribution of trial types, the trials 
were arranged into two and six blocks for acquisition and generalization phases, 
respectively. In addition, an equal number of each trial type was used for the recording of 
psychophysiological measures (recorded in odd trials) and risk ratings (recorded in even 
trials). ITI trials were intermixed with CS and GSs trials across the experimental session 
(six in pre-acquisition, 12 in acquisition and generalization). In half of the ITI trials, startle 
probes were also presented. There was a 5 min break between the acquisition and 
generalization phases. Self-reported levels of anxiety and arousal evoked by CS+ and CS- 
were collected using 10-point Likert scale following acquisition and generalization phases. 
                                                                                                                                                                                 
so on. Such size increments resulted in ring diameters, from smallest to largest, of 2.00, 2.30, 2.60, 2.90, 3.20, 3.50, 3.80, 4.10, 4.40, and 
4.70 in. 
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Additionally, after the experiment, participants rated the discomfort produced both by the 
US and the startle probe on a 1 (no discomfort) to 10 (maximum discomfort) scale; and 
answered a multiple-choice question (based on Dawson & Reardon, 1973) regarding 
contingency awareness (“The electric stimulus usually appeared: a) in the presence of the 
smallest ring; b) in the presence of the biggest ring; c) randomly; d) I don’t know”). 
Individuals who correctly identified the stimulus that co-occurred with the US were 
considered contingency-aware. 
 
Physiological recordings 
Physiological responses were recorded using the BIOPAC Mod. MP150WSW 
recording system (Biopac Systems Inc., Santa Barbara, CA). The startle blink response was 
measured by recording the electromyographic activity (EMG) of the orbicularis oculi, using 
two 0.5 cm Ag/AgCl surface electrodes and following standard guidelines (Blumenthal et 
al., 2005). Impedance level was maintained below 5 kΩ. The raw EMG signal was sampled 
at a rate of 2000 Hz, filtered to reduce power line noise (analogue 50 Hz notch filter) and to 
attenuate the frequencies beyond the EMG spectrum (infinite impulse response band-pass 
filter, cut-off frequencies of 28 and 500 Hz), and then rectified and smoothed off-line (10 
ms moving window average), using the AcqKnowledge v.4.1 software (Biopac Systems, 
Inc, Santa Barbara, CA). 
 
Data reduction and response definition 
The onset latency window for the startle response was 20 to 100 ms and the peak 
magnitude was determined within 150 ms of response onset. Startle amplitudes were 
computed in microvolts (µV) as the difference between the EMG value at response peak 
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and the average EMG during the baseline period (50 ms preceding startle probe onset). In 
those trials in which no response was detected, amplitude was scored as 0 µV. After visual 
inspection, trials with excessive baseline activity were rejected. The number of rejected 
trials was not different between groups [GAD: 3.11%, HC: 2.65%; χ2(1) = 6.79, p > .05]. 
Prior to statistical analysis, startle responses were T-transformed for each participant 
individually and for each phase separately. For online risk ratings, one GAD participant 
was excluded from the analysis due to technical problems.  
 
 
Data analysis 
 Differences in variables related to the experimental procedure were assessed with 
t-tests. Preliminary analyses for overall startle reactivity during the whole experiment were 
performed by repeated-measures ANOVA of startle responses during ITI trials (raw data). 
Factors were phase/block (pre-acquisition, first block of acquisition, second block of 
acquisition, and generalization) and group (GAD, HC). Additionally, a 2 (GAD, HC) x 9 
(all 9 trials of the habituation phase) ANOVA was computed to analyze habituation to the 
startle probe before the experiment began. 
Data were analyzed separately for (1) preacquisition and acquisition and (2) 
generalization, and for each measure (risk ratings and startle EMG), using 
repeated-measures ANOVAs (GLM procedure). In preacquisition and acquisition, stimulus 
(CS- and CS+) and phase (preacquisition, acquisition) were entered as within-subjects 
factors, and group (GAD and HC) was entered as a between-subjects factor. Additionally, 
to assess differential dynamics during acquisition, a 2x3x2 ANOVA was conducted for 
each measure, with type of CS and Block (Acquisition 1, Acquisition 2, Acquisition 3) as 
within-subjects and Group as between-subjects factor. 
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Generalization analyses included stimulus (CS-, class 1, class 2, class 3, class 4, and 
CS+) as within-subjects and group (GAD and HC) as between-subjects factor. All 
ANOVAs were followed by t-tests (and trend analyses in the case of generalization) when 
necessary. As in Lissek et al. (2010, 2013), quadratic trend analyses were specially 
important to test the shape of generalization gradients because it was expected that GAD 
participants (but not HC) would depart from the quadratic function found in healthy 
humans (see Lissek et al., 2010). Bivariate Pearson correlations were calculated to assess 
the relationship between GAD features (C-D scale and STAI-T scores) and our conditioned 
fear-generalization indexes. Between-groups differences in risk ratings and retrospective 
reports to the CS- were calculated with independent sample t-tests. Gender was excluded 
from the final analyses because it did not interact with the other factors, indicating that 
participants’ gender did not affect conditioned fear-acquisition or generalization. EMG was 
analyzed using T-scores as well as raw data. Because similar results were obtained, only 
T-scores are presented. We report ηp2 as a measure of effect size for main and interaction 
effects. Data were analyzed with SPSS 20. All analyses were conducted in GAD 
participants with no comorbidity (n=23) and repeated in GAD participants with 
comorbidity (n=28). 
 
Results 
Preliminary analyses 
As expected, GAD patients had statistically significant higher scores on the 
STAI-T, STAI-S, and ASI-3. GAD patients also showed higher ratings for the discomfort 
elicited by the startle probe than the HC. There were no differences between groups 
regarding awareness of the CS-US contingency, selected intensity of the US, and ratings of 
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the discomfort produced by the shock (Table 1). In addition, groups did not differ in startle 
reactivity across the experiment, F(3, 153) = .57, p = .60, ηp2 = .01, or in startle habituation 
before the experimental phases F(8, 336) = 1.08, p = .37, ηp2 = .03. The results of the these 
preliminary analyses were identical for GAD participants with comorbidity.  
 
Preacquisition and acquisition 
Risk ratings. A main effect of type of Stimulus, F(1, 49) = 38.50, p < .001, ηp2 = .44, 
a main effect of Group, F(1, 49) = 3.90, p = .05, ηp2 = .07, as well as a main effect of Phase 
F(1, 49) = 79.64, p <  .001, ηp2 = .61,  were found. Moreover, the Stimulus x Phase 
interaction was significant, F(1, 49) = 28.54, p < .001, ηp2 = .37, driven by significantly 
increased risk ratings to the CS+ versus CS- during the acquisition, t(50) = 8.30, p < .001, 
but not during the preacquisition, t(50) = 1.83, p = .08, indicating successful fear 
acquisition for the whole sample. However, neither the Stimulus x Group nor the Stimulus 
x Phase x Group interactions were significant, both Fs < 1.22, ps > .28, ηp2< .02, showing 
that fear acquisition was similar in GAD and HC. Additionally, t-tests showed that risk 
ratings to the CS- during the acquisition phase were not significantly different between 
groups, t(49) = 1.01, p = .32. Results were identical for GAD participants with comorbidity. 
 
EMG. A main effect of type of Stimulus was found, F(1, 51) = 32.44, p < .001, ηp2 = 
.39. Additionally, the Stimulus x Phase interaction was significant F(1, 51) = 4.47, p = .04, 
ηp2 = .08, and was driven by significantly increased startle to the CS+ versus CS- during the 
acquisition, t(52) = 2.80, p < .001, but not during the preacquisition phase, t(52) = .63, p = 
.53. Similar to the Risk Ratings results, neither the Stimulus x Group nor the Stimulus x 
Phase x Group interactions were significant, both Fs < .26, ps > .61, ηp2< .02, showing that 
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fear acquisition was similar in GAD and HC. Results were identical for GAD participants 
with comorbidity. 
The results of the ANOVA focusing on acquisition rate using the 3 acquisition blocks 
revealed increased risk ratings for the CS+ versus the CS- for all 3 blocks and greater 
startle EMG for the CS+ versus the CS- in blocks 1 and 3 (see Table 2). The Stimulus × 
Group interaction was not significant, F(1, 100) = .09, p = .76, ηp2 = .01, indicating that the 
“speed” of fear acquisition was similar in GAD and HC. Again, same results were obtained 
for GAD participants with comorbidity.  
 
Table 2.  
 
Means and standard deviations in the Preacquisition and Acquisition phases, for EMG and 
Risk Ratings by groups 
 
PHASE Non-comorbid GAD participants (GAD participants with comorbidity) Healthy controls 
 CS+ CS- CS+ CS- 
 Mean SD Mean SD Mean SD Mean SD 
EMG  
PRECON 58.45 
 (58.76) 
7.38  
(7.79) 
58.22 
(58.31) 
5.72 
(5.44) 
57.06 
 
6.42 
 
58.53 
 
6.97 
 
CON 54.71 
(55.05) 
4.23 
(4.57) 
52.33 
(52.01) 
3.24 
(3.11) 
53.84 
 
4.66 
 
51.75 
 
4.30 
 
CON_1 54.61 
(55.04) 
6.58 
(6.71) 
53.12 
(53.26) 
5.20 
(5.16) 
56.11 
 
7.28 
 
53.27 
 
6.47 
 
CON_2 55.97 
(56.28) 
6.74 
(6.92) 
53.26 
(52.77) 
5.90 
(5.78) 
53.41 
 
6.51 
 
52.41 
 
6.61 
 
CON_3 53.31 
(53.59) 
8.11 
(7.59) 
50.38 
(49.93) 
5.76 
(5.34) 
51.83 
 
6.09 
 
49.58 
 
6.10 
 
RISK RATINGS  
PRECON 1.59 
(1.62) 
0.67 
(0.65) 
1.29 
(1.38) 
0.45 
(0.55) 
1.19 
 
0.42 
 
1.19 
 
0.48 
 
CON 2.27 
(2.24) 
0.58 
(0.59) 
1.35 
(1.41) 
0.37 
(0.49) 
2.17 
 
0.66 
 
1.22 
 
0.47 
 
CON_1 1.97 
(1.95) 
0.45 
(.48) 
1.33 
(1.45) 
0.58 
(0.65) 
1.63 
 
0.58 
 
1.23 
 
0.55 
 
CON_2 2.38 
(2.39) 
0.77 
(0.73) 
1.45 
(1.45) 
0.61 
(0.58) 
2.25 
 
0.75 
 
1.23 
 
0.57 
 
CON_3 2.26 
(2.25) 
0.64 
(.67) 
1.29 
(1.35) 
0.51 
(0.62) 
2.43 
 
0.74 
 
1.20 
 
0.47 
 
PRECON; Preconditioning phase, CON; conditioning phase, CON_1; Block 1 of conditioning phase, 
CON_2; Block 2 of conditioning phase, CON_3; Block 3 of conditioning phase, SD; Standard Deviation. 
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Retrospective Anxiety and Arousal. There was also evidence of fear conditioning 
for the whole sample in the retrospective self-reports of anxiety and arousal, as shown by a 
main effect of type of Stimulus, both Fs > 64.02, ps < .001, ηp2 > .55, driven by greater 
reported anxiety and arousal to the CS+ compared to the CS- in both GAD (both ps <  
.001) and HC (both ps <  .001). The Stimulus × Group interaction was not significant, 
both Fs < .74, ps > .34, ηp2 < .01, indicating that these differences were similar across 
groups. Although this interaction was not significant, t-tests showed between-group 
differences in the retrospective ratings of the CS-, with GAD patients showing higher 
anxiety (M = 3.18, SD = 2.12 vs M=1.40, SD=1.40) and arousal (M = 4.04, SD = 2.61 vs 
M=2.43, SD=2.05) than HC, both ts(50) > 2.50, all ps< .01. Identical results were obtained 
for GAD participants with comorbidity.  
 
Conditioned fear-generalization 
Risk ratings. Generalization of fear conditioning was evidenced by main effects of 
Stimulus type in both GAD, F(5, 100) = 17.61, p < .001, ηp2 = .46, and HC, F(5, 140) = 
41.54, p < .001, ηp2 = .60 indicating that participants responses varied as a function of the 
stimuli presented. Comparison of risk ratings to each stimulus with ratings to the CS- (α set 
at p < .01) within each group revealed that GAD participants showed greater risk ratings to 
the CS+ than to the CS-, t(20) = 6.26, p < .001 as well as greater risk ratings to all GSs in 
comparison to the CS-, all ts(2) > 2.46, ps < .02. A similar pattern was observed for HC, 
with greater risk ratings to the CS+ than to the CS-, t(28) = 7.64, p < .001, and with greater 
ratings to class 4, 3 and 2 GSs; all ts(28) > 1.54, ps < .00. Only ratings to class 1 GSs did 
 17
not differ from ratings to CS-, ts(28) = 1.54, ps = .13. Generalization of risk ratings 
therefore extended to all GSs in GAD participants and to all but one GSs in HC. However, 
the main effect of Group, F(1, 48) = .12, p = .73, ηp2 = .00 and the Stimulus Χ Group 
interaction were not significant, F(5, 240) = 2.00, p = .14, ηp2 = .04 (Figure 1). Moreover, 
independent sample t-tests showed that risk ratings to the CS- during the generalization 
phase were similar across groups, t(48) = .88, p = .38.  
Analyses for GAD participants with comorbidity were almost identical except for the 
Stimulus Χ Group interaction that in this case was significant: F(5, 255) = 2.87, p = .01, 
ηp2 = .05. However, this was not attributable to between group-differences in the quadratic 
component of the generalization gradients of the groups (the Stimulus × Group quadratic 
trend was not significant; F(1, 51) = 1.83, p = .18) but rather to the fact that GAD patients 
with comorbidity reported higher risk to class 1 GS than HC, t(52) = 2.21, p = .02. 
 
Figure 1.  
Generalization gradients by group. Bars represent standard errors of the mean. 
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EMG. For the whole sample, a main effect of type of Stimulus was found, F(5, 255) 
=13.19,p < .001, ηp2 = .21. Generalization of startle responses across stimuli was analyzed 
by comparing responses elicited during the presentation of the CS- with responses elicited 
during each GSs for each group, with α adjusted by means of a Bonferroni correction (p < 
.05/5 = .01). Paired-samples t tests in GAD subjects showed that startle responses elicited 
during the presentation of the CS+ were significantly higher than responses elicited during 
the CS-, t(22) = 3.28, ps = .00. Additionally, responses elicited during the class 4 and class 
3 GSs were also greater than those elicited during the CS-, both ts(22) > 3.86, ps < .001. In 
contrast, responses elicited during the presentation of the class 2 and class 1 GSs did not 
differ from responses elicited during the CS-, both ts(22) < 1.25, ps > .05. Paired-samples t 
tests in HC showed the same pattern. Startle responses elicited during the presentation of 
the CS+ were significantly higher than responses elicited during the CS-, t(29) = 2.62, ps = 
.01.  Additionally, responses elicited during the class 4 and class 3 GSs were also greater 
than those elicited during the CS-, both ts(29) > 1.99, ps < .05. Only responses elicited 
during the presentation of the class 2 and class 1 GSs did not differ from responses elicited 
during the CS-, both ts(29) < .95, ps > .05. Thus, conditioned fear, as measured by startle 
potentiation, extended to the class 4 and class 3 GSs. However, the generalization gradient 
did not differ across groups, as indicated by a non-significant Stimulus × Group interaction 
F(5, 255) = .88, p > .05, ηp2 = .02 (Figure 2). Identical results were obtained for the GAD 
group with comorbidity.  
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Figure 2.  
Generalization gradients by group. Bars represent standard errors of the mean. 
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Following Lissek et al. (2013), the shape of generalization gradients was also 
assessed by calculating the degree to which each gradient departed from linearity using the 
equation: linear departure = ([CS+ + CS-] ⁄2) – ([GS1 + GS2 + GS3 + GS4] ⁄4). Risk 
ratings results indicated that linear departures for GAD participants (M = .20, SD = .26) 
and HC (M = .09, SD = .31) were not significantly different, t(51) = 1.32, p = .19. 
Standardized startle data were similar with GAD participants (M = -1.77, SD = 3.44) and 
HC (M = .12, SD = 3.16) not being significantly different, t(52) = .33, p = .75. Both 
measures were not either significantly different for GAD participants with comorbidity.   
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Overall self-reported anxiety and arousal following the generalization phase 
revealed a main effect of type of Stimulus, both Fs > 53.98, ps < .001, ηp2 > .51, driven by 
greater reported anxiety and arousal to the CS+ compared to the CS- in both GAD (both ps 
<  .001) and HC (both ps <  .001). Similar to the acquisition phase, the Stimulus × Group 
interaction was not significant, both Fs < .74, p > .34, ηp2 = .01. Although this interaction 
was not significant, t-tests showed between-group differences in the retrospective ratings of 
the CS-, with GAD patients showing higher anxiety (M = 2.81, SD = 2.08 vs M=1.57, 
SD=1.38 respectively) and arousal (M = 3.18, SD = 2.20 vs M = 1.80, SD = 1.69 
respectively) than HC, both ts(50) > 2.60, all ps< .03. Results for GAD participants with 
comorbidity were almost identical, with a non-significant Stimulus × Group interaction 
(both Fs < .58, p > .45, ηp2 = .01) but t-tests showing between-group differences in the 
retrospective ratings of the CS-and GAD participants showing higher anxiety (M = 2.83, 
SD = 2.24 vs M=1.57, SD=1.38 respectively) and arousal (M = 3.12, SD = 2.49 vs M = 
1.80, SD = 1.69 respectively) than HC, both ts(52) > 2.32, all ps< .02. 
 
 
Complementary analyses 
Given the significant difference between groups, we repeated our analyses using the 
variable ‘startle probe discomfort’ as a covariate, but results (using both GAD participants 
with and without comorbidity) remained unchanged (data not shown but analyses available 
upon request).  
 The difference in the risk ratings to the CS+ and to the CS- in the preacquisition 
phase approached significance (p = .08). Given this unexpected finding, we repeated our 
analyses excluding those subjects whose difference score (CS+ - CS-) during preacquisition 
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was 0.5 points above or below 0 (GAD, n= 6; HC, n= 2). This rendered the Stimulus x 
Group interaction during preacquisition non-significant (p = .97). After this, acquisition and 
generalization results remained unchanged. We also compared the number of participants 
for each group that received the largest or smallest ring as CS+. This proportion was not 
different across groups (GAD: largest ring = 10; smallest ring = 12; HC: largest ring = 16; 
smallest ring = 14; χ2 = .32, p = .58). The same set of analyses using GAD participants with 
comorbidity yielded almost identical results, except for the Stimulus X Group interaction 
during generalization, that now became non-significant (p = .10). 
 
Discussion 
 
In the present study, we aimed to examine fear acquisition and generalization in 
GAD patients using a fear conditioning paradigm assessing FPS and subjective responses. 
As expected, GAD patients and controls did not differ as regards fear acquisition. However, 
contrary to our hypothesis, both groups did not differ in most indexes of conditioned 
fear-generalization.  
There are very few studies that have investigated fear acquisition in GAD using a 
fear conditioning paradigm and are comparable to ours. The study by Thayer et al. (2000) 
mentioned in the introduction used a higher-order conditioning procedure. An earlier study 
by Pitman and Orr (1986) found no differences in differential conditioning during 
acquisition between GAD patients (as defined by DSM-III criteria) and controls, but 
comparison with this study is difficult given the changes in GAD criteria from DSM-III-R 
onwards. These changes emphasized the concept of GAD as a separate disorder, its 
duration/persistence (change from 1 to 6 months) and focused on the role of worry. 
Therefore only the study by Lissek et al. (2013) has investigated fear conditioning in GAD 
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as it is currently defined in the DSM-IV-TR (APA, 2000) or DSM-V (APA, 2013) and 
using a similar paradigm.  
In terms of acquisition, our results agree with those of Lissek et al. (2013) and 
indicate that GAD individuals have “normal” fear acquisition. Some previous differential 
conditioning studies in PD (Lissek et al., 2009) or PTSD (Jovanovic et al., 2009, 2010) 
suggest that these patients have difficulties in suppressing fear responses to the CS- (i.e., 
deficits in inhibition learning) but this question has not specifically been investigated in 
GAD (see Lissek et al., 2005). In any case, it must be noted that most previous studies 
conducted in this area do not provide a direct test of differences in inhibition learning (see 
Mineka & Oehlberg, 2008). Recently, new experimental methods have been developed 
(Jovanovic et al., 2005; Kindt & Soeter, 2014), which can assess the independent 
contributions of fear excitation and fear inhibition, although, to our knowledge, they have 
not been tested in GAD. 
The present results on fear acquisition are also in agreement with studies that have 
found that (non-clinical) individuals with high trait anxiety show similar fear acquisition 
than those with low trait-anxiety (Fredrikson & Georgiades, 1992; Otto et al., 2007; 
Pineles, Vogt, & Orr, 2009; Torrents-Rodas et al., 2013).  Nevertheless, as stated in the 
introduction, results are not conclusive (see Baas, van Ooijen, Goudriaan, & Kenemans 
2008; Indovina et al., 2011; Gazendam, Kamphuis, & Kindt, 2013). Recent research 
suggests that complex fear conditioning paradigms (e.g. the blocking and the 
protection-from-overshadowing procedure) may be better suited than the “typical” 
differential fear conditioning paradigm to detect individual differences variables involved 
in fear conditioning (Arnaudova et al., 2013; see Beckers et al., 2013).  
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The hypothesized greater conditioned fear-generalization in patients as compared to 
controls was overall not confirmed. The only signs of increased conditioned 
fear-generalization emerged for retrospective ratings of the CS-, that were (or tended to be) 
higher among GAD participants and for the risk ratings to the generalization stimuli, that 
suggested also a slightly higher tendency to generalize in GAD. This is surprising because 
we used the same paradigm as Lissek et al. (2013). Apart from small socio-demographic 
differences (our sample was slightly younger; M = 24 versus M = 31 in Lissek et al. and 
100% Caucasian versus 73% in Lissek et al.), there seem to be few differences between 
Lissek et al. study (2013) and ours. The main difference is that half of the patients in Lissek 
et al. (2013) had a comorbid anxiety disorder. Also, our ratings of discomfort for the startle 
probe were higher for the GAD than for the HC group (this information is not reported in 
Lissek et al. study), but controlling for this variable did not change our results. It could also 
be argued that the discomfort ratings for the US in our study are relatively low, but they 
were similar in both groups, and this should have affected (and it did not) fear acquisition. 
As in Lissek et al. (2013), we did not find between-group differences during acquisition. 
This is important given the effects that differential fear acquisition may have on 
conditioned fear-generalization (see Dunsmoor, Mitroff, & LaBar, 2009).  
Our generalization results are in line with another recent study assessing 
conditioned fear-generalization in GAD (Greenberg et al., 2013). In this study, conditioned 
fear-generalization gradients -as assessed with pupillary responses or risk ratings3- were 
similar for GAD patients and healthy controls. This was an instructed fear study, but results 
on conditioned fear-generalization seem to be comparable whether participants are 
informed on the CS-US contingencies or learn them through direct experience (see 
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Greenberg et al., 2013). It must be noted, however, that 50% of GAD patients in this study 
had comorbid major depression. The current results are also in agreement with a previous 
non-clinical study from our group, where conditioned fear-generalization gradients were 
compared among individuals with different levels of trait anxiety (as measured with the 
STAI-T) and no differences emerged (Torrent-Rodas et al., 2013).  
 If the results of our study were replicated, we would then need to answer the 
question: Why are GAD patients not characterized by enhanced fear generalization?  
First, it is important to note that conditioned fear-generalization may occur along 
different dimensions. In the current work (as well as in Lissek et al., 2013 and Greenberg et 
al., 2013 studies) the focus was on conditioned fear-generalization based on a dimension of 
physical similarity. However, generalization may also occur along a dimension of fear 
intensity. In fact, a recent study suggests that generalization of conditioned fear in humans 
is determined by fear intensity rather than physical similarity (Dunsmoor, Mitroff, & 
LaBar, 2009).  It could be the case that GAD (or other anxiety disorders) is characterized 
by abnormalities in conditioned fear-generalization determined by the former rather than 
the latter.  Similarly, research on conditioned fear-generalization in humans so far has 
mainly focused on dimensional stimulus changes, but it has been shown that discrete 
feature changes may also influence generalization (Vervliet & Geens, 2013). To what 
extent these two mechanisms (generalization based on fear intensity or feature learning) are 
involved in anxiety disorders remains unknown.  
Also, most previous studies in anxiety disorders have focused on cued conditioned 
fear-generalization and very little research has been conducted on context fear 
generalization. This is especially important in GAD (see below) because chronic anxiety 
                                                                                                                                                                                 
In the Greenberg et al. (2013) study risk ratings were collected post-task, not online, as in ours and in Lissek et al. (2013) study.  
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seems to be better modeled as the result from context rather than cue conditioning (Davis, 
1998; Luyten, Vansteenwegen, van Kuyck, Gabriëls, & Nuttin, 2011).  
Second, it could be the case that conditioned fear-generalization abnormalities 
characterize some anxiety disorders but not others. So far, evidence for abnormal 
conditioned fear-generalization has been mainly found in PD (Lissek et al., 2010). 
Although both PD and GAD are currently classified as anxiety disorders, they differ in 
many aspects. Panic disorder involves fear of specific stimuli (for example, somatic 
experiences), whereas GAD is characterized by more diffuse anxiety. More importantly, 
whereas high arousal could be associated with PD, decreased arousal seems to characterize 
GAD (Hoehn-Saric, McLeod, & Zimmerli, 1989; Hoehn-Saric, McLeod, Funderburk, & 
Kowalski, 2004). Previous studies suggest that fear sensitization (i.e., an enhanced fear 
response after experiencing intense fear) plays an important role in conditioned 
fear-generalization (Dunsmoor, Mitroff, & LaBar, 2009). Given that increases in general 
arousal may sensitize some fear-relevant stimuli (see, for example, Öhman & Mineka, 
2001), it is therefore possible that only anxiety disorders characterized by increased arousal 
show augmented conditioned fear-generalization.  
Third, as stated in the introduction, the emphasis of current models of GAD is not 
on variables related to fear acquisition/generalization. Other mechanisms, especially those 
related to the avoidance of internal affective experiences, may play a greater role in the 
etiology of GAD (see Borkovec, Alcaine, & Behar, 2004; Behar et al., 2009). 
 We tested acquisition and generalization effects in GAD patients with and 
without anxious comorbidity but the results were almost identical. It may be argued that 
testing GAD participants with no comorbidity limits the generalizability of our findings 
because comorbidity is the rule rather than the exception in GAD. However, it is important 
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to note that GAD is not “more comorbid” than other anxiety disorders, at least at an 
epidemiological level (Kessler, 2000; Kessler, Keller, & Wittchen, 2001). The high 
comorbidity seen in clinical samples in GAD is an artifact of treatment-sample selection 
rather than inherent to the disorder (Wittchen, 2002; Kessler, 2000). Moreover, a better 
understanding of non-comorbid GAD is important because it is associated with significant 
impairment in both adult (Bruce, Machan, Dyck, & Keller, 2001) and pediatric (Alfano, 
2012) samples. On the other hand, the fact that we repeated our analyses GAD participant 
with comorbidity provides a unique perspective on the possible effects of comorbidity on 
fear conditioning abnormalities, a topic which has received little attention so far. If we 
assume that comorbidity is an index of severity (i.e, that patients with comorbidity are 
generally more severe than non-comorbid ones), one interesting possibility is that these 
abnormalities may be significantly associated with severity (current symptom) rather than 
the presence/absence of the disorder, as seen in a recent study in PTSD patients (Jovanovic 
et al., 2010). Moreover, this would be in agreement with data showing that fear learning 
abnormalities are also present in other “non-anxiety” disorders such as schizophrenia (see 
Holt, Coombs, Zeidan, Goff, & Milad, 2012). Although our results suggest that anxious 
comorbidity does not make a significant difference, it is still possible that “other 
comorbidities” have an effect on variables related to fear learning. In this repect, a 
limitation of our study is that we did not measure depressive symptoms, which may 
influence fear conditioning processes (Dibbets, van den Broek, & Evers, 2014). Another 
limitation is aht other dimensional instruments for GAD are available (e.g. the Penn-State 
Worry Questionnaire; Meyer, Miller, Metzger, & Borkovec, 1990) which probably tap 
better into the GAD construct and which should be used in future investigations.   
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To summarize, we did not find that overall GAD patients differ from healthy 
controls in conditioned fear acquisition or generalization. Although great advances have 
been made to study etiological accounts on GAD, much is still unclear. Future 
investigations should address associative as well as non-associative processes involved in 
the disorder. On a broader scale, further research is needed on the role of comorbidity in 
fear learning abnormalities in anxiety disorders. 
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